PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Read More…
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone919-786-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.07 billion
Profitability
Miscellaneous
Employees16,400
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable
PRA Health Sciences (NASDAQ:PRAH) Frequently Asked Questions
What is PRA Health Sciences' stock symbol?
PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."
How were PRA Health Sciences' earnings last quarter?
PRA Health Sciences Inc (NASDAQ:PRAH) posted its quarterly earnings results on Thursday, February, 20th. The medical research company reported $1.54 EPS for the quarter, beating the consensus estimate of $1.32 by $0.22. The medical research company had revenue of $800.24 million for the quarter, compared to analyst estimates of $794.91 million. PRA Health Sciences had a net margin of 7.93% and a return on equity of 28.52%. The firm's revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the company earned $1.31 earnings per share. View PRA Health Sciences' Earnings History.
When is PRA Health Sciences' next earnings date?
What guidance has PRA Health Sciences issued on next quarter's earnings?
PRA Health Sciences updated its FY20 earnings guidance on Thursday, February, 20th. The company provided earnings per share (EPS) guidance of $5.77-5.97 for the period, compared to the Thomson Reuters consensus estimate of $5.81. The company issued revenue guidance of $3.23-3.36 billion, compared to the consensus revenue estimate of $3.32 billion.
What price target have analysts set for PRAH?
10 equities research analysts have issued 1 year price objectives for PRA Health Sciences' stock. Their forecasts range from $100.00 to $128.00. On average, they expect PRA Health Sciences' stock price to reach $117.11 in the next year. This suggests a possible upside of 24.9% from the stock's current price. View Analyst Price Targets for PRA Health Sciences.
What is the consensus analysts' recommendation for PRA Health Sciences?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 6 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PRA Health Sciences.
Has PRA Health Sciences been receiving favorable news coverage?
Media headlines about PRAH stock have been trending very negative this week, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. PRA Health Sciences earned a news impact score of -3.0 on InfoTrie's scale. They also gave news articles about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for PRA Health Sciences.
Are investors shorting PRA Health Sciences?
PRA Health Sciences saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,460,000 shares, an increase of 17.7% from the January 15th total of 2,090,000 shares. Based on an average daily trading volume, of 523,200 shares, the days-to-cover ratio is presently 4.7 days. Currently, 3.9% of the shares of the stock are short sold. View PRA Health Sciences' Current Options Chain.
Who are some of PRA Health Sciences' key competitors?
Some companies that are related to PRA Health Sciences include Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Icon (ICLR), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL) and Auxly Cannabis Group (CBWTF).
What other stocks do shareholders of PRA Health Sciences own?
Who are PRA Health Sciences' key executives?
PRA Health Sciences' management team includes the folowing people:
- Mr. Colin Shannon, Chairman, CEO & Pres (Age 60)
- Mr. Michael J. Bonello, Exec. VP, CFO & Corp. Sec. (Age 49)
- Mr. Kent Thoelke, Exec. VP & Chief Scientific Officer
- Mr. Thomas Byrne, VP of Legal Affairs
- Christine Rogers, Director of PR & Corp. Communications
When did PRA Health Sciences IPO?
(PRAH) raised $306 million in an initial public offering (IPO) on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.
Who are PRA Health Sciences' major shareholders?
PRA Health Sciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Capital Research Global Investors (4.07%), Janus Henderson Group PLC (3.10%), Massachusetts Financial Services Co. MA (2.70%), State Street Corp (2.27%), Pendal Group Ltd (1.52%) and Standard Life Aberdeen plc (1.23%). Company insiders that own PRA Health Sciences stock include Fund Holdings LP Kkr and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.
Which major investors are selling PRA Health Sciences stock?
PRAH stock was sold by a variety of institutional investors in the last quarter, including Standard Life Aberdeen plc, Bank of New York Mellon Corp, AQR Capital Management LLC, Pictet Asset Management Ltd., Capital Research Global Investors, Artemis Investment Management LLP, Acadian Asset Management LLC and Strs Ohio. View Insider Buying and Selling for PRA Health Sciences.
Which major investors are buying PRA Health Sciences stock?
PRAH stock was acquired by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Janus Henderson Group PLC, Captrust Financial Advisors, FMR LLC, Goldman Sachs Group Inc., Mackay Shields LLC, Assenagon Asset Management S.A. and Franklin Resources Inc.. View Insider Buying and Selling for PRA Health Sciences.
How do I buy shares of PRA Health Sciences?
Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is PRA Health Sciences' stock price today?
One share of PRAH stock can currently be purchased for approximately $93.74.
How big of a company is PRA Health Sciences?
PRA Health Sciences has a market capitalization of $5.96 billion and generates $3.07 billion in revenue each year. The medical research company earns $243.02 million in net income (profit) each year or $4.80 on an earnings per share basis. PRA Health Sciences employs 16,400 workers across the globe.View Additional Information About PRA Health Sciences.
What is PRA Health Sciences' official website?
How can I contact PRA Health Sciences?
PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]
MarketBeat Community Rating for PRA Health Sciences (NASDAQ PRAH)
MarketBeat's community ratings are surveys of what our community members think about PRA Health Sciences and other stocks. Vote "Outperform" if you believe PRAH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAH will underperform the S&P 500 over the long term. You may vote once every thirty days.
